<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="899">
  <stage>Registered</stage>
  <submitdate>28/09/2005</submitdate>
  <approvaldate>28/09/2005</approvaldate>
  <nctid>NCT00229697</nctid>
  <trial_identification>
    <studytitle>Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study</studytitle>
    <scientifictitle>A Phase II Randomised, Double-Blind, Stratified, Multi-Centre Trial Comparing the Nolvadex 20 Mg And Placebo Combination To The Nolvadex 20 Mg and ZD1839 (IRESSA) 250 MG Combination In Patients With Metastatic Breast Cancer And Estrogen Receptor (ER) and/or Progesterone (PR) Positive Tumours</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>D7917C00225</secondaryid>
    <secondaryid>1839IL/0225</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast Neoplasms</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Gefitinib
Treatment: drugs - Tamoxifen

Experimental: 1 - ZD1839 + Nolvadex

Other: 2 - Nolvadex + placebo


Treatment: drugs: Gefitinib


Treatment: drugs: Tamoxifen


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Strata 1: To compare the time to progression between 2 treatment arms (ZD1839/Nolvadex vs placebo/Nolvadex)</outcome>
      <timepoint>Time to progression (progressive disease or death; equivalent to progression-free survival)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Strata 2: To compare the clinical benefit rate between 2 treatment arms (ZD1839/Nolvadex vs placebo/Nolvadex)</outcome>
      <timepoint>Overall clinical benefit rate: Complete Response, Partial Response or Stable Disease &gt; 24weeks after each combination</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To compare the clinical benefit rate between 2 treatment arms (ZD1839/Nolvadex vs placebo/Nolvadex) in Strata 1 and overall</outcome>
      <timepoint>Overall clinical benefit rate: Complete Response, Partial Response or Stable Disease &gt;24 weeks after each combination. Objective tumour resp defined according to RECIST criteria</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare time to progression between 2 treatment arms (ZD1839/Nolvadex vs placebo/Nolvadex) in Strata 2 and overall</outcome>
      <timepoint>Time to progression (progressive disease or death)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare the objective response rate between ZD1839/Nolvadex and placebo/Nolvadex in each strata and overall</outcome>
      <timepoint>Objective tumour response (OR) defined according to RECIST criteria</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To estimate duration of response for the ZD1839/Nolvadex and placebo/Nolvadex treatments in each strata and overall</outcome>
      <timepoint>Duration of response (CR and PR)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare overall survival between the ZD1839/Nolvadex and placebo/Nolvadex in each strata</outcome>
      <timepoint>Overall survival</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess whether patients with high tumour levels of HER-2 and/or AIB1 demonstrate de novo resistance to Nolvadex therapy or have shorter TTP or response duration when compared with Nolvadex/ZD1839 treatment</outcome>
      <timepoint>Time to progression (progressive disease or death), duration of response (CR and PR)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare the objective response rate between the ZD1839/Nolvadex and placebo/Nolvadex treatment arms in the subset of all patients with ER+ tumours staining 2+/3+ for Her2neu by IHC</outcome>
      <timepoint>Objective tumour response (OR) defined according to RECIST criteria</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare the safety and tolerability of ZD1839/Nolvadex to placebo/Nolvadex</outcome>
      <timepoint>Safety (frequency and severity of adverse events)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine steady-state plasma trough concentrations of tamoxifen in all patients and to compare between the ZD1839/Nolvadex and placebo/Nolvadex treatment arms</outcome>
      <timepoint>Tamoxifen (Cmin) steady-state plasma concentration</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine steady-state plasma trough concentrations of ZD1839 and relate values to historical data</outcome>
      <timepoint>ZD1839 (Cmin) steady-state plasma concentration</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To relate steady-state plasma trough concentrations of ZD1839 to demographic, response, and safety variables</outcome>
      <timepoint>ZD1839 (Cmin) steady-state plasma concentration</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the quality of life (QOL) and symptom relief based on the Functional Assessment of Cancer Therapy - Breast (FACT-B) on both treatment arms</outcome>
      <timepoint>FACT-B questionnaire, FBSI (FACT-B Symptom Index)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To investigate subject hospital resource use and health status</outcome>
      <timepoint>Hospitalisations and EQ-5D</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Characterization of specific adverse events</outcome>
      <timepoint>Characterization of adverse events such as alopecia, rash and diarrhea</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To obtain tumour tissue for biologic studies in this patient population</outcome>
      <timepoint>ER receptor, ErbB-1 &amp;2 (immunohistochemistry) and other biological markers including Her2/neu, AIB1</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Histologically confirmed metastatic adenocarcinoma of the breast (seeTNM staging
             Appendix I) that is ER and/or PR positive as determined in local laboratories at each
             investigator site (central verification of ER status will be performed after the
             patient starts treatment

          -  A tissue block from either the metastatic or primary tumor site is required.

          -  WHO performance status (PS) 0-2

          -  Patients must not be pregnant or breast-feeding. A negative pregnancy test is required
             within 7 days prior to randomization if pre- or peri-menopausal. Postmenopausal
             patients are defined as:

          -  natural menopause with last menses &gt; 1 year ago,

          -  radiation induced oophorectomy with last menses &gt; 1 year ago,

          -  chemotherapy induced menopause with 1 year interval since last menses, or

          -  serum FSH and LH and plasma estradiol levels in the postmenopausal range for the
             institution.

          -  bilateral oophorectomy</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>130</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients cannot be on hormone replacement therapy or received prior chemotherapy for
             metastatic disease.

          -  Patients previously treated with a Tyrosine Kinase inhibitor or have evidence of an
             active interstitial lung disease are not eligible.

          -  Treatment with LH-RH analog.

          -  Laboratory values as follow Bilirubin &gt;1.5 times upper limit of normal ULN, alanine
             amino transferase (ALT) or aspartate amino transferase (AST) &gt;2.5 times the ULN if no
             demonstrable liver metastases, or &gt;5 times the ULN in the presence of liver metastases

          -  Bone marrow function: WBC &lt;1500 mm3</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>317</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Research Site - Bentleigh East</hospital>
    <hospital>Research Site - Newcastle</hospital>
    <hospital>Research Site - Randwick</hospital>
    <hospital>Research Site - Westmead</hospital>
    <hospital>Research Site - Wodonga</hospital>
    <postcode> - Bentleigh East</postcode>
    <postcode> - Newcastle</postcode>
    <postcode> - Randwick</postcode>
    <postcode> - Westmead</postcode>
    <postcode> - Wodonga</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Bahía Blanca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Ciudad de Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Córdoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>El Palomar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Resistencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Rosario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>San Miguel de Tucuman</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Santa Fe</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Vicente Lopez</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Wilrijk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Belo Horizonte</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Curitiba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Porto Alegre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>São Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>New Brunswick</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Herlev</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon Cedex 08</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Mougins</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Poitiers</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rouen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Jena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Kiel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>München</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Trier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Durban</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Johannesburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Klerksdorp</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Observatory</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Córdoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Majadahonda</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Zaragoza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Colchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Dundee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Nottingham</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AstraZeneca</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is being carried out to see if ZD1839 is effective in treating metastatic breast
      cancer in combination with Nolvadex, and if so, how it compares with Nolvadex alone.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00229697</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>AstraZeneca Iressa Medical Science Director, MD</name>
      <address>AstraZeneca</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>